Your First Drug's Approved and Launched...Now What?
Executive Summary
FDA new drug approvals are making a comeback, and a group of biopharma first-timers are leading the way. To understand the challenges they face in the transition from discovery to commercialization, IN VIVO looked at 50 companies spanning the past 10 years. Finally reaching the US market might be a biotech's defining moment, but for those who build to last, there could be more rewards beyond that first approval.
You may also be interested in...
Antibody-Drug Conjugates: The Next Generation Of Moving Parts
The next generation of antibody-drug conjugates have much room for improvement: engineered proteins, drugs, the linkers that bond them together, and perhaps even new targets to attack. All their complexity is an invitation to innovation, but will the parts come together into products that prove safe and efficacious in the clinic?
Financings Of The Fortnight Sees A Venture Capital Trend: Identify And Bring In The Buyer Early
Plus news on recent financings by Ember Therapeutics, Aviir, Covidien and Ariad Pharmaceuticals.
Bridging The Gap Between Sell- And Buy- Sides In Biopharma Business Development
The biotech financing drought, combined with increasing externalization of pharma R&D, should be creating an ideal climate for successful dealmaking. Yet executing partnerships between biopharma sellers and buyers remains incredibly challenging. Locust Walk Partners surveyed senior business development executives to find the keys to executing mutually satisfying deals.